Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877329 | 0.97 | MAOA (0.49) | BAZ2BMAOAALDH1A1HPGDKDM4E | |
| SCHEMBL1612079 | 0.90 | MAOA (0.51) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL21098726 | 0.83 | NPC1 (0.46) | BAZ2BMAOAALDH1A1HPGDKDM4E | |
| SCHEMBL18992141 | 0.81 | JAK2 (0.42) | MAOAALDH1A1MAPT | |
| SCHEMBL8312077 | 0.80 | CYP2A6 (0.44) | BAZ2BMAOAALDH1A1RAB9AMAPT | |
| SCHEMBL22815827 | 0.80 | SMN1; SMN2 (0.43) | MAOAALDH1A1HPGDKDM4EGAA | |
| SCHEMBL1613763 | 0.79 | ALDH1A1 (0.68) | ALDH1A1KDM4ENPC1RAB9AMEN1 | |
| SCHEMBL30567324 | 0.79 | ALDH1A1 (0.68) | ALDH1A1KDM4ENPC1RAB9AMEN1 | |
| SCHEMBL7652191 | 0.78 | BAZ2B (0.44) | BAZ2BMAOAALDH1A1HPGDKDM4E | |
| SCHEMBL4867460 | 0.77 | NPC1 (0.41) | MAOAALDH1A1HPGDKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-01-28 | — | — | US | disclosed |
| EP-3423431-B1 | CARBAMATE DERIVATIVE COMPOUNDS AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| EP-3423431-B1 | CARBAMATE DERIVATIVE COMPOUNDS AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| EP-4265616-A1 | SPIROCYCLIC COMPOUND AS KRAS-G12C INHIBITOR | Shanghai Euregen Biopharma Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-4209492-A1 | COMPOUND FOR TREATING THROMBOTIC DISEASES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2023-07-12 | — | — | EP | disclosed |
| EP-3883932-B1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-3328835-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-12 | — | — | EP | disclosed |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20050075366-A1 | 4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same | ALLERGAN, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20040220402-A1 | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds | ALLERGAN, INC. | 2004-11-04 | — | — | US | disclosed |
| US-6407115-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS; SIDE EFFECT REDUCTION, WATER SOLUBILITY | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| US-5834476-A | DERIVATIVE OF CAMPTOTHECIN, ANTITUMOR AGENT, ANTICARCINOGENIC AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5770605-A | Method for treating leukemia with a hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-06-23 | — | — | US | disclosed |
| US-5658920-A | ANTITUMOR AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5637770-A | Hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-10 | — | — | US | disclosed |
| EP-0495432-B1 | Hexa-cyclic compound | DAIICHI SEIYAKU CO (JP) | 1996-05-29 | — | — | EP | disclosed |
| EP-0495432-A1 | Hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-07-22 | — | — | EP | disclosed |
| US-4016281-A | Tetralone and indanone compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220402-A1 | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds | ADRB2, ADRA2C, ADRB1 | BAZ2B 4222/4885MAOA 1962/4885ALDH1A1 669/4885 |
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | GLI1, GLI2, SHH | BAZ2B 18/4885MAOA 4212/4885ALDH1A1 1281/4885 |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | BAZ2B 528/4885MAOA 82/4885ALDH1A1 1924/4885 |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | BAZ2B 528/4885MAOA 82/4885ALDH1A1 1924/4885 |
| US-20050075366-A1 | 4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same | ADRB2, ADRA2C, ADRA2B | BAZ2B 3221/4885MAOA 2211/4885ALDH1A1 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.